Worth reading
40Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
13.2
% (adjusted EBITDA year on year)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Summary of Q&AFirst quarter of the fiscal year ending March 20277 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Operating profitExpected to decline by double digits year on year (figure is Not disclosed)
Ordinary incomeExpected to decline by double digits year on year (figure is Not disclosed)
Full-year earnings forecast
Adjusted EBITDA
¥22.1 million+13.2%
Operating profitDecline of double digits year on year (figure is Not disclosed)
Ordinary incomeDecline of double digits year on year (figure is Not disclosed)
Bio business revenue23.3% increase year on year
Pharmaceutical business revenue4.4% increase year on year
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
The company views progress as broadly steady.Key points of the Q&AKey questions raised by investors at the briefing and the company's answers
- Background to the disclosure of the previously undecided full-year outlook and changes in raw-material procurement conditions
- Why adjusted EBITDA is expected to increase while operating profit and ordinary profit are expected to decline
- Details of the strategic expenses required to secure future projects
- Costs of addressing raw-material procurement risks and their expected future impact
- Difference in growth rates between the bio and pharmaceutical fields
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Strategic expenses required to win future projects-¥70 million
- Costs to address raw-material procurement risksOperating loss of ¥10 million
- Higher depreciation expenses associated with the operation of FP-4Increase of more than ¥400 million year on year
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- Procurement conditions for crude oil and other materials
- Prices of raw materials such as solvents
- Progress toward supply chain stabilization
New initiatives
- Developing and assessing alternative procurement sources
- Verifying and improving manufacturing procedures for the mass production of projects in the development stage
Medium-term management plan targets
The company states that initiatives in each business field are progressing in line with its growth scenario. Target values and fiscal years are Not disclosedRisk amount incorporated into the outlookThe amount representing the range of variation the company expects in its forecast.
A conservative assumption incorporating risks to a certain extent (amount is Not disclosed)| Item | Details |
|---|---|
| Document type | Summary of Q&A |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Operating profit | Expected to decline by double digits year on year (figure is Not disclosed) |
| Ordinary income | Expected to decline by double digits year on year (figure is Not disclosed) |
| Full-year earnings forecast | Adjusted EBITDA ¥22.1 million (YoY +13.2%) / Operating profit Decline of double digits year on year (figure is Not disclosed) / Ordinary income Decline of double digits year on year (figure is Not disclosed) / Bio business revenue 23.3% increase year on year / Pharmaceutical business revenue 4.4% increase year on year |
| Self-assessment against the plan | The company views progress as broadly steady. |
| Breakdown of Factors Affecting the Change | Factors Strategic expenses required to win future projects / Amount -¥70 million, Factors Costs to address raw-material procurement risks / Amount Operating loss of ¥10 million, Factors Higher depreciation expenses associated with the operation of FP-4 / Amount Increase of more than ¥400 million year on year |
| Assumptions Underlying the Business Outlook | Procurement conditions for crude oil and other materials, Prices of raw materials such as solvents, Progress toward supply chain stabilization |
| Risk amount incorporated into the outlook | A conservative assumption incorporating risks to a certain extent (amount is Not disclosed) |
| Medium-term management plan targets | The company states that initiatives in each business field are progressing in line with its growth scenario. Target values and fiscal years are Not disclosed |
| Key points of the Q&A | Background to the disclosure of the previously undecided full-year outlook and changes in raw-material procurement conditions, Why adjusted EBITDA is expected to increase while operating profit and ordinary profit are expected to decline, Details of the strategic expenses required to secure future projects, Costs of addressing raw-material procurement risks and their expected future impact, Difference in growth rates between the bio and pharmaceutical fields |
| New initiatives | Developing and assessing alternative procurement sources, Verifying and improving manufacturing procedures for the mass production of projects in the development stage |
Items this document does not state (19)
Net SalesNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastSegment resultsKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / Share
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company disclosed its full-year outlook because procurement conditions for crude oil and other materials improved, while logistics bottlenecks and supply chain disruptions began to ease. Meanwhile, higher depreciation expenses associated with the operation of FP-4 are expected to weigh on operating profit and ordinary profit.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.